Probiotics and Antimicrobial Proteins

, Volume 3, Issue 1, pp 1–7 | Cite as

Gut Microbiota is Not Modified by Randomized, Double-Blind, Placebo-Controlled Trial of VSL#3 in Diarrhea-Predominant Irritable Bowel Syndrome

Article

Abstract

Irritable bowel syndrome (IBS) is a common condition that negatively impacts the quality of life for many individuals. The exact etiology of this disorder is largely unknown; however, emerging studies suggest that the gut microbiota is a contributing factor. Several clinical trials show that probiotics, such as VSL#3, can have a favorable effect on IBS. This double-blind, randomized placebo-controlled study has been conducted in diarrhea-predominant IBS subjects in order to investigate the effect of VSL#3 on the fecal microbiota. The bacterial composition of the fecal microbiota was investigated using high-throughput microarray technology to detect 16S RNA. Twenty-four subjects were randomized to receive VSL#3 or placebo for 8 weeks. IBS symptoms were monitored using GSRS and quality-of-life questionnaires. A favorable change in Satiety subscale was noted in the VSL #3 groups. However, the consumption of the probiotic did not change the gut microbiota. There were no adverse events or any safety concerns encountered during this study. To summarize, the use of VSL#3 in this pilot study was safe and showed improvement in specific GSRS-IBS scores in diarrhea-predominant IBS subjects. The gut microbiota was not affected by VSL#3 consumption, suggesting that the mechanism of action is not directly linked to the microbiota.

Keywords

Irritable bowel syndrome Diarrhea Probiotics Microbiota 

References

  1. 1.
    Suau S (2003) Molecular tools to investigate intestinal bacterial communities. J Pediatr Gastroenterol Nutr 37(3):222–224CrossRefGoogle Scholar
  2. 2.
    Treem WR, Ahsan N, Kastoff G, Hyams JS (1996) Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation. J Pediatr Gastroenterol Nutr 23(3):280–286CrossRefGoogle Scholar
  3. 3.
    King TS, Elia M, Hunter JO (1998) Abnormal colonic fermentation in irritable bowel syndrome. Lancet 352(9135):1187–1189CrossRefGoogle Scholar
  4. 4.
    Pimentel M, Mayer AG, Park S, Chow EJ, Hasan A, Kong Y (2003) Methane production during lactulose breath test is associated with gastrointestinal disease presentation. Dig Dis Sci 48(1):86–92CrossRefGoogle Scholar
  5. 5.
    Pimentel M, Kong Y, Park S (2004) IBS subjects with methane on lactulose breath test have lower postprandial serotonin levels than subjects with hydrogen. Dig Dis Sci 49(1):84–87CrossRefGoogle Scholar
  6. 6.
    Codling C, O’Mahony L, Shanahan F, Quigley EM, Marchesi JR (2009) A molecular analysis of fecal and mucosal bacterial communities in irritable bowel syndrome. Dig Dis Sci 55(2):392–397CrossRefGoogle Scholar
  7. 7.
    Tana C, Umesaki Y, Imaoka A, Handa T, Kanazawa M, Fukudo S (2009) Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 22(5):512–519, 114–515Google Scholar
  8. 8.
    Parkes GC, Brostoff J, Whelan K, Sanderson JD (2008) Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103(6):1557–1567CrossRefGoogle Scholar
  9. 9.
    Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133(1):24–33CrossRefGoogle Scholar
  10. 10.
    Hoveyda N, Heneghan C, Mahtani KR, Perera R, Roberts N, Glasziou P (2009) A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 9:15CrossRefGoogle Scholar
  11. 11.
    Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M (2008) Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 51(12):1775–1780CrossRefGoogle Scholar
  12. 12.
    McFarland LV, Dublin S (2008) Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 14(17):2650–2661CrossRefGoogle Scholar
  13. 13.
    Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D (2001) Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 152(8):735–741CrossRefGoogle Scholar
  14. 14.
    Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR (2003) A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17(7):895–904CrossRefGoogle Scholar
  15. 15.
    Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR (2005) A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17(5):687–696CrossRefGoogle Scholar
  16. 16.
    Paliy O, Kenche H, Abernathy F, Michail S (2009) High-throughput quantitative analysis of the human intestinal microbiota with a phylogenetic microarray. Appl Environ Microbiol 75(11):3572–3579CrossRefGoogle Scholar
  17. 17.
    Collins SM (1996) The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111(6):1683–1699CrossRefGoogle Scholar
  18. 18.
    Drossman DA, Camilleri M, Mayer EA, Whitehead WE (2002) AGA technical review on irritable bowel syndrome. Gastroenterology 123(6):2108–2131CrossRefGoogle Scholar
  19. 19.
    Quigley EM (2003) Current concepts of the irritable bowel syndrome. Scand J Gastroenterol 38(Suppl 237):1–8CrossRefGoogle Scholar
  20. 20.
    Bradley HK, Wyatt GM, Bayliss CE, Hunter JO (1987) Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome. J Med Microbiol 23(1):29–32CrossRefGoogle Scholar
  21. 21.
    Gorbach SL (2002) Probiotics in the third millennium. Dig Liver Dis 34(Suppl 2):S2–S7CrossRefGoogle Scholar
  22. 22.
    von Wright A, Salminen S (1999) Probiotics: established effects and open questions. Eur J Gastroenterol Hepatol 11(11):1195–1198CrossRefGoogle Scholar
  23. 23.
    Isolauri E, Kirjavainen PV, Salminen S (2002) Probiotics: a role in the treatment of intestinal infection and inflammation? Gut 50(Suppl 3):III54–III59CrossRefGoogle Scholar
  24. 24.
    McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O’Sullivan GC, Kiely B, Collins JK et al (2003) Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 52(7):975–980CrossRefGoogle Scholar
  25. 25.
    O’Mahony L, Feeney M, O’Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O’Sullivan G, Shanahan F, Collins JK (2001) Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 15(8):1219–1225CrossRefGoogle Scholar
  26. 26.
    Mack DR, Michail S, Wei S, McDougall L, Hollingsworth MA (1999) Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol 276(4 Pt 1):G941–G950Google Scholar
  27. 27.
    Michail S, Abernathy F (2003) Lactobacillus plantarum inhibits the intestinal epithelial migration of neutrophils induced by enteropathogenic Escherichia coli. J Pediatr Gastroenterol Nutr 36(3):385–391CrossRefGoogle Scholar
  28. 28.
    Jiang T, Savaiano DA (1997) In vitro lactose fermentation by human colonic bacteria is modified by Lactobacillus acidophilus supplementation. J Nutr 127(8):1489–1495Google Scholar
  29. 29.
    Jiang T, Mustapha A, Savaiano DA (1996) Improvement of lactose digestion in humans by ingestion of unfermented milk containing Bifidobacterium longum. J Dairy Sci 79(5):750–757CrossRefGoogle Scholar
  30. 30.
    Jiang T, Savaiano DA (1997) Modification of colonic fermentation by Bifidobacteria and pH in vitro. Impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci 42(11):2370–2377CrossRefGoogle Scholar
  31. 31.
    Ouwehand AC, Isolauri E, Kirjavainen PV, Tolkko S, Salminen SJ (2000) The mucus binding of Bifidobacterium lactis Bb12 is enhanced in the presence of Lactobacillus GG and Lact. delbrueckii subsp. bulgaricus. Lett Appl Microbiol 30(1):10–13CrossRefGoogle Scholar
  32. 32.
    Ouwehand AC, Lagstrom H, Suomalainen T, Salminen S (2002) Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 46(3–4):159–162CrossRefGoogle Scholar
  33. 33.
    Ford AC, Talley NJ, Quigley EM, Moayyedi P (2009) Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 52(10):1805 (author reply 1806)Google Scholar
  34. 34.
    Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS (2009) The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 104(4):1033–1049 (quiz 1050)CrossRefGoogle Scholar
  35. 35.
    Bausserman M, Michail S (2005) The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 147(2):197–201CrossRefGoogle Scholar
  36. 36.
    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B (2000) Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 95(5):1231–1238CrossRefGoogle Scholar
  37. 37.
    Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F (2004) Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 5(4):169–174CrossRefGoogle Scholar
  38. 38.
    Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME (1996) Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 91(8):1579–1585Google Scholar
  39. 39.
    Hamilton-Miller J (2001) Probiotics in the management of irritable bowel syndrome: a review of clinical trials. Microb Ecol Health Dis 13:212–216CrossRefGoogle Scholar
  40. 40.
    Gaudier E, Michel C, Segain JP, Cherbut C, Hoebler C (2005) The VSL# 3 Probiotic Mixture Modifies Microflora but Does Not Heal Chronic Dextran-Sodium Sulfate-Induced Colitis or Reinforce the Mucus Barrier in Mice. J Nutr 135(12):2753–2761Google Scholar
  41. 41.
    Langendijk PS, Schut F, Jansen GJ, Raangs GC, Kamphuis GR, Wilkinson MH, Welling GW (1995) Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus-specific 16S rRNA-targeted probes and its application in fecal samples. Appl Environ Microbiol 61(8):3069–3075Google Scholar
  42. 42.
    Wilson KH, Blitchington RB (1996) Human colonic biota studied by ribosomal DNA sequence analysis. Appl Environ Microbiol 62(7):2273–2278Google Scholar
  43. 43.
    Suau A, Bonnet R, Sutren M, Godon JJ, Gibson GR, Collins MD, Dore J (1999) Direct analysis of genes encoding 16S rRNA from complex communities reveals many novel molecular species within the human gut. Appl Environ Microbiol 65(11):4799–4807Google Scholar
  44. 44.
    Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122):1027–1031CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2010

Authors and Affiliations

  1. 1.Wright State Boonshoft School of MedicineDaytonUSA

Personalised recommendations